American Society Of Clinical Oncology
Geriatric oncology award recipient aims to ‘right-size’ cancer treatment for older adults
William Dale, MD, PhD, FASCO, has experienced a range of emotions since learning he’d receive the B.J. Kennedy Geriatric Oncology Award at this year’s ASCO Annual Meeting.
‘Substantial’ contributions: More than 20% of patients participate in cancer research
More than 20% of patients with cancer participate in some form of clinical study, and that number is considered a “floor” estimate, according to study results published in Journal of Clinical Oncology.
Guidelines: Optimizing vaccinations a ‘critical component’ of effective cancer care
New guidelines for vaccinating adults with solid or hematologic cancers detailed the importance of vaccination optimization, multidisciplinary coordination and vaccination of household members.
New ASCO president aims to improve access, return ‘humanity’ to cancer care
As Robin T. Zon, MD, FACP, FASCO, prepares to begin her term as ASCO president, she hopes to leverage one of the profession’s greatest resources — people.
Patient and Physician Advocacy with Ashley Sumrall, MD
In this episode, host Shikha Jain, MD, speaks with Ashley Sumrall, MD, about advocacy outside of their oncology practices and organizations, what lies ahead for the field of neuro-oncology and more.
Language minimizing adverse events in abstracts ‘harmful,’ can affect patient care
Use of subjective minimizing terminology, such as “safe” and “tolerable,” when discussing treatment-related toxicities occurs frequently at oncology and hematology conferences, according to a study published in Journal of Cancer Policy.
Precision Medicine and Personalized Care with George Sledge, MD
In this episode, host Shikha Jain, MD, speaks with George Sledge, MD, about patient feedback benefiting leadership decision-making, the future of precision medicine in oncology and more.
Marijuana use associated with lower rates of prostate cancer
Active and former marijuana users reported significantly lower prevalence of prostate cancer compared with nonusers, according to data presented at ASCO Genitourinary Cancers Symposium.
Pembrolizumab after surgery shows ‘practice changing’ survival benefit for kidney cancer
Adjuvant therapy with pembrolizumab following nephrectomy conferred significant improvement in OS compared with placebo among adults with renal cell carcinoma who had a high risk for disease recurrence, study results showed.
‘Disappointing’ results question the utility of liquid biopsy-guided cancer treatment
Circulating tumor DNA did not successfully predict whether patients with resected stage II colon cancer would benefit from adjuvant chemotherapy, according to findings presented at ASCO Gastrointestinal Cancers Symposium.